Literature DB >> 24440053

Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients.

Yousang Ko1, Byeong-Ho Jeong2, Hye Yun Park2, Won-Jung Koh2, Gee Young Suh3, Man Pyo Chung2, O Jung Kwon2, Kyeongman Jeon4.   

Abstract

PURPOSE: The outcomes and predictors of mortality from Pneumocystis pneumonia (PCP) in HIV-negative patients requiring mechanical ventilation (MV) for respiratory failure were evaluated.
MATERIALS AND METHODS: This retrospective observational study enrolled 48 patients with PCP requiring MV in the medical intensive care unit (ICU). Multiple logistic regression analysis was used to identify independent predictors of in-hospital mortality.
RESULTS: The main conditions underlying the PCP were malignancies (60%) or post solid organ transplant (35%). Excluding four patients whose initial treatment was changed due to adverse reactions, 21 (44%) of 44 patients did not respond to the initial treatment. During the ICU stay, additional complications developed: shock in 22 (46%), ventilator-associated pneumonia in 16 (33%), and acute kidney injury in 15 (31%). Ultimately, 31 (65%) patients died while hospitalised. In multivariate analysis, hospital mortality was independently associated with severity of illness on ICU admission, failure of initial antimicrobial treatment for PCP, and newly developed shock during ICU stay.
CONCLUSIONS: PCP in HIV-negative patients requiring MV for respiratory failure remains a serious illness with high mortality. Failure of the initial antimicrobial treatment for PCP as well as severity of illness was independent predictors of poor outcomes.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neoplasms; Outcomes; Pneumocystis pneumonias; Respiratory insufficiency

Mesh:

Year:  2013        PMID: 24440053     DOI: 10.1016/j.jcrc.2013.12.005

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  17 in total

1.  Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Authors:  Philip N Okafor; Francis A Farraye; Adetoro T Okafor; Daniel O Erim
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

2.  Supplementary Role of Immunological Indicators in the Diagnosis and Prognosis of Pneumocystis Pneumonia in Non-HIV Immunocompromised Patients.

Authors:  Yaoqian Cao; Jiayue Chen; Lixia Dong
Journal:  Infect Drug Resist       Date:  2022-08-21       Impact factor: 4.177

3.  Do inhaled corticosteroids increase the risk of Pneumocystis pneumonia in people with lung cancer?

Authors:  Sameh Msaad; Ilhem Yangui; Najla Bahloul; Narjes Abid; Makram Koubaa; Yosr Hentati; Mounir Ben Jemaa; Samy Kammoun
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

4.  Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus.

Authors:  Katrien Lagrou; Sharon Chen; Henry Masur; Claudio Viscoli; Catherine F Decker; Livio Pagano; Andreas H Groll
Journal:  Clin Infect Dis       Date:  2021-03-12       Impact factor: 9.079

5.  Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death.

Authors:  Minjiang Chen; Xinlun Tian; Fang Qin; Jiong Zhou; Jinjing Liu; Mengzhao Wang; Kai-Feng Xu
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

6.  Intermittent Courses of Corticosteroids Also Present a Risk for Pneumocystis Pneumonia in Non-HIV Patients.

Authors:  Maria L Calero-Bernal; Isabel Martin-Garrido; Mikel Donazar-Ezcurra; Andrew H Limper; Eva M Carmona
Journal:  Can Respir J       Date:  2016-09-18       Impact factor: 2.409

7.  Risk Factors of Mortality From Pneumocystis Pneumonia in Non-HIV Patients: A Meta-Analysis.

Authors:  Yuqiong Wang; Xiaoyi Zhou; Maidinuer Saimi; Xu Huang; Ting Sun; Guohui Fan; Qingyuan Zhan
Journal:  Front Public Health       Date:  2021-06-16

8.  Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway.

Authors:  Stine Grønseth; Tormod Rogne; Raisa Hannula; Bjørn Olav Åsvold; Jan Egil Afset; Jan Kristian Damås
Journal:  BMC Infect Dis       Date:  2021-07-07       Impact factor: 3.090

Review 9.  Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review.

Authors:  Magdalena Sokulska; Marta Kicia; Maria Wesołowska; Andrzej B Hendrich
Journal:  Parasitol Res       Date:  2015-08-19       Impact factor: 2.289

10.  Relationship between Radiological Stages and Prognoses of Pneumocystis Pneumonia in Non-AIDS Immunocompromised Patients.

Authors:  Xiang-Dong Mu; Peng Jia; Li Gao; Li Su; Cheng Zhang; Ren-Gui Wang; Guang-Fa Wang
Journal:  Chin Med J (Engl)       Date:  2016-09-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.